Lavestra H (Losartan Potassium, Hydrochlorothiazide)

Losartan potassium blocks the angiotensin II type 1 (AT1) receptors, preventing the hormone from causing blood vessels to narrow, reducing aldosterone release, and limiting sodium and water retention. This leads to vasodilation, decreased blood volume, and ultimately lower blood pressure.

The specific dose of Lavestra H is determined by the prescribing clinician based on the patient’s blood pressure, renal function, electrolyte status, and overall health. Dosage adjustments are individualized, and patients should follow the exact regimen provided by their healthcare professional.

Lavestra H is classified as Pregnancy Category D, indicating evidence of fetal risk and it should be avoided during pregnancy. It is also not recommended while breastfeeding because the drug may pass into breast milk and affect the infant. Alternative therapies should be discussed with a healthcare provider.

To request Lavestra H, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lavestra H combines an angiotensin II receptor blocker (losartan) with a thiazide diuretic (hydrochlorothiazide), offering dual mechanisms that many single‑agent therapies lack. Compared with monotherapy, the combination can achieve better blood‑pressure control with a single pill, but clinicians must consider individual tolerance, electrolyte balance, and renal function.

Lavestra H tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children.

Lavestra H is taken orally, usually once daily, with or without food, as directed by a healthcare professional. Swallow the tablet whole with a full glass of water and do not crush or chew it unless specifically instructed.

Serious risks include severe dehydration, electrolyte disturbances (especially low potassium), acute kidney injury, hyperkalemia, angioedema, and marked hypotension that can lead to fainting. Patients should seek immediate medical attention if they experience swelling of the face or throat, rapid weight loss, or persistent dizziness.

Lavestra H should be avoided in patients with known hypersensitivity to losartan, hydrochlorothiazide, or any component of the formulation. It is contraindicated in pregnancy, in individuals with severe renal impairment, and in those with anuria. Caution is also advised for patients with severe liver disease or electrolyte abnormalities.